Gabapentin

Gabapentin has been studied in 49 papers since 2016: 17 observational studies in people, 5 in animals, 1 in cells, 25 reviews; 23 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Non-hormonal management of menopause symptoms—the statement of the European Society of Gynecology”.

InterventionApproved 1993

49 papers study it7 more mention it19 findingsUpdated

PubChemChEBIMeSH

6 new papers in 30 daysSee all 56 papers on gabapentin

At a glance

The findings reach people, from one lab or study. 6 independent labs in 3 countries; 208 trials, 5 about aging, 87 with no results posted.

“No difference in mortality was observed between groups (adjusted hazard ratio and 95% confidence interval for gabapentin + opioids 0.98 [0.90-1.06]; P = 0.63).”
Mortality after concurrent treatment with gabapentin and opioids in older adults with spine diagnosesPain2024doi:10.1097/j.pain.0000000000003448

1 of its findings points the other way.

Worms or flies, mice and humans: a single group. Cells: nothing yet.
  • 6 independent labs in 3 countries
  • 1 finding against
  • 208 trials, 5 about aging, 87 with no results posted
  • Funders: National Institutes of Health and 6 more
  • 18 of 208 trials sponsored by its developers
  • Humans17
  • Animals4
  • Model organisms1
  • Cells1

What did studies of gabapentin find?

10

Studies of gabapentin measured 10 outcomes, among them mortality, vasomotor symptoms and hot flashes.

Mortality

no changein humans2HR 0.98

2 studies
  1. Gabapentin was not clearly linked with mortality in humans (spine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioids) (aHR 0.98 (95% CI 0.90-1.06), P = 0.63).

    “No difference in mortality was observed between groups (adjusted hazard ratio and 95% confidence interval for gabapentin + opioids 0.98 [0.90-1.06]; P = 0.63).”

    Humansspine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioidsfemale 66.7%sn = 134,266

    Mortality after concurrent treatment with gabapentin and opioids in older adults with spine diagnoses

    Pain

  2. Gabapentin was not clearly linked with mortality in humans (concurrent opioid treatment in people with spine diagnoses) (adjusted HR 0.98 (0.90, 1.06)).

    “No difference in mortality was observed between groups (adjusted hazard ratio (HR) and 95% confidence interval (CI) for gabapentin + opioids was 0.98 (0.90, 1.06); p=0.63).”

    Humansconcurrent opioid treatment in people with spine diagnosesmedian 45 days66.7% femalesn = 134,266

    Mortality with concurrent treatment with gabapentin and opioids among people with spine diagnoses in the U.S. Medicare population: a propensity-matched cohort study

    medRxiv : the preprint server for health sciencesPreprint

Vasomotor symptoms

downin humans1

1 study
  1. Gabapentin decreases vasomotor symptoms in humans (for vasomotor symptoms in patients with cancer).

    “strong evidence supporting selective serotonin and norepinephrine reuptake inhibitors, gabapentin, and lifestyle interventions for vasomotor symptoms”

    Reviewfor vasomotor symptoms in patients with cancer

    Menopause Management in Patients With Cancer

    Obstetrics and gynecology

Hot flashes

downin humans1

1 study
  1. Gabapentin decreases hot flashes in humans (breast cancer patients receiving endocrine therapy) (25–69% reduction).

    “Pharmacological options, including SSRIs (e.g., paroxetine, escitalopram), SNRIs (e.g., venlafaxine, desvenlafaxine), and gabapentin, have shown more consistent reductions in hot flash frequency and severity (25–69%)”

    Reviewbreast cancer patients receiving endocrine therapy

    Non-hormonal treatments for hot flashes in breast cancer patients: a narrative review

    Future Journal of Pharmaceutical Sciences

tau phosphorylation

upin mice1

1 study
  1. Gabapentin increases tau phosphorylation in mice.

    “In the hippocampus of GBP-treated mice, increased levels of p-tau (S416) and p-tau (S262) were observed”

    Animalshippocampus60 daysfemales

    Long-term gabapentin treatment impairs cognitive function in aged mice via tau hyperphosphorylation

    Frontiers in pharmacology

Learning and memory

downin mice1

1 study
  1. Gabapentin impairs learning and memory in mice with or without nerve injury-induced pain.

    “Long-term GBP treatment impaired learning and memory in aged mice with or without nerve injury-induced pain”

    Animalswith or without nerve injury-induced pain60 daysfemales

    Long-term gabapentin treatment impairs cognitive function in aged mice via tau hyperphosphorylation

    Frontiers in pharmacology

Vasomotor symptoms

downin humans1

1 study
  1. Gabapentin decreases vasomotor symptoms in humans (menopause).

    “Gabapentin, and Pregabalin are effective for managing vasomotor symptoms as well as other menopausal symptoms.”

    Reviewmenopausefemales

    Non-oestrogen-based and complementary therapies for menopause

    Best practice & research. Clinical endocrinology & metabolism

More on Vasomotor symptoms

Fragility fracture

no changein humans1HR 1.02

1 study
  1. Gabapentin was not clearly linked with fragility fracture in humans (Gabapentin initiation compared with pregabalin initiation) (HR 1.02 (95% CI 0.86–1.21) versus pregabalin).

    “short-term risk of fragility fractures among gabapentin initiators was not different compared to those initiating pregabalin.”

    HumansGabapentin initiation compared with pregabalin initiation90 days

    The risk of fragility fractures following initiation of gabapentin and pregabalin-A Danish, nationwide, high-dimensional propensity score-matched cohort study

    Basic & clinical pharmacology & toxicology

More on Fragility fracture

Physical function

downin humans1OR 1.78

1 study
  1. Gabapentin is linked with worse physical function in humans (initially normal cognition) (OR 1.78, 95% CI 1.12–2.83).

    “and mean of FAQ at index+2 visit (1.78 [1.12, 2.83]).”

    Humansinitially normal cognition

    The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition

    Frontiers in pharmacology

Cognitive function

downin humans1OR 1.55

1 study
  1. Gabapentin is linked with worse cognitive function in humans (initially normal cognition) (OR 1.55, 95% CI 1.07–2.25).

    “Gabapentin initiation was significantly associated with cognitive/functional status decline: worsening CDRGLOB at index+1 visit (odds ratio [95% confidence interval]: 1.55 [1.07, 2.25])”

    Humansinitially normal cognition

    The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition

    Frontiers in pharmacology

Motor function

upin flies1

1 study
  1. Gabapentin improves motor function in hFUS-Q290X transgenic flies.

    “The involvement of the GABAergic pathway was supported by rescue of motor symptoms with gabapentin.”

    Model organismsin hFUS-Q290X transgenic flies

    FUS-linked essential tremor associated with motor dysfunction in Drosophila

    Human genetics

What is gabapentin linked with?

4

Studies link gabapentin with 4 measures, among them dementia, major medical complication and falls.

Dementia

upin humans2no changein humans1HR 1.09–7.39

2 studies
  1. Gabapentin is associated with dementia in patients without CKD (HR 1.09; 95% CI, 0.89-1.34).

    “versus a near-null association in patients without CKD (HR 1.09; 95% CI, 0.89-1.34; P=0.41)”

    Humansin patients without CKD

    Chronic Kidney Disease Amplifies Gabapentin-Associated Dementia Risk in Non-Dialysis Patients: Findings Consistent with a Renal Pharmacokinetic Vulnerability

    medRxiv : the preprint server for health sciencesPreprint

  2. Gabapentin is linked with a higher risk of dementia in patients with CKD (HR 7.39; 95% CI, 3.43-15.92).

    “gabapentin was associated with substantially elevated dementia risk in patients with CKD (hazard ratio [HR] 7.39; 95% CI, 3.43-15.92; P<0.001)”

    Humansin patients with CKD

    Chronic Kidney Disease Amplifies Gabapentin-Associated Dementia Risk in Non-Dialysis Patients: Findings Consistent with a Renal Pharmacokinetic Vulnerability

    medRxiv : the preprint server for health sciencesPreprint

  3. Gabapentin is linked with a higher risk of dementia in humans among patients also taking a CCB (vs pregabalin) (time-varying HR, 1.52 [95% CI, 1.23–1.89]).

    “gabapentin initiation was associated with higher dementia incidence among patients also taking a CCB than among those not taking a CCB (time-varying HR, 1.52 [95% CI, 1.23–1.89]”

    Humansamong patients also taking a CCB (vs pregabalin)n = 33,791

    Concurrent Gabapentin and Dihydropyridine Calcium Channel Blocker Use and Risk of Incident Dementia: An Active-Comparator Cohort Study

    medRxivPreprint

More on Dementia

Major medical complication

upin humans2HR 1.02

2 studies
  1. Gabapentin is linked with a higher risk of major medical complication in humans (spine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioids) (aHR 1.02 (95% CI 1.00-1.04), P = 0.03).

    “people treated with gabapentin + opioids were at slightly increased risk of a major medical complication (1.02 [1.00-1.04]; P = 0.03)”

    Humansspine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioidsfemale 66.7%sn = 134,266

    Mortality after concurrent treatment with gabapentin and opioids in older adults with spine diagnoses

    Pain

  2. Gabapentin is linked with a higher risk of major medical complication in humans (concurrent opioid treatment in people with spine diagnoses) (adjusted HR 1.02 (1.00, 1.04)).

    “people treated with gabapentin + opioids were at slightly increased risk of a major medical complication (1.02 (1.00, 1.04); p=0.03) compared to those treated with TCAs/duloxetine + opioids.”

    Humansconcurrent opioid treatment in people with spine diagnosesmedian 45 days66.7% femalesn = 134,266

    Mortality with concurrent treatment with gabapentin and opioids among people with spine diagnoses in the U.S. Medicare population: a propensity-matched cohort study

    medRxiv : the preprint server for health sciencesPreprint

Falls

upin humans2OR 2.5–2.51

2 studies
  1. Gabapentin is associated with falls in humans (older adults with cognitive impairment) (OR 2.5, 95% CI 1.3-4.6).

    “gabapentin initiation was significantly associated with increased odds of new falls at the index + 2 visit (odds ratio [95% confidence interval] 2.5 [1.3, 4.6]).”

    Humansolder adults with cognitive impairment2 years (index + 2 visit)

    The Association of Gabapentin Initiation with Cognitive and Behavioral Changes in Older Adults with Cognitive Impairment: A Retrospective Cohort Study

    Drugs & aging

  2. Gabapentin is linked with a higher risk of falls in humans (initially normal cognition, excluding extant motor dysfunction) (OR 2.51, 95% CI 1.19–5.31).

    “in this sample, gabapentin initiation was associated with increased falls at the index+2 visit (2.51 [1.19, 5.31]).”

    Humansinitially normal cognition, excluding extant motor dysfunction

    The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition

    Frontiers in pharmacology

Incident dementia

upin humans1HR 2.44

1 study
  1. Gabapentin is associated with incident dementia in humans (IPTW HR 2.44, 95% CI 1.06–5.63, p=0.036).

    “When gabapentin was added to a regimen that already included a DHP-CCB, incident dementia risk was elevated relative to pregabalin”

    HumansHypertension; gabapentin added after prior dihydropyridine calcium channel blocker therapy, compared with pregabalinn = 7,141

    Does Medication Order Matter? Incident Dementia Risk When Gabapentin Is Added to Prior Dihydropyridine Calcium Channel Blocker Therapy: An Active-Comparator Cohort Study in Hypertensive Adults

    medRxivPreprint

More on Incident dementia

Has gabapentin been tested in people?

5 of 208 about aging

Yes: 17 observational studies in people have been published, and 207 trials are registered.

Approved

All 8

Repurposing

40 of 109

Every condition in trials

  • Abuse potential

    Phase 4Results posted2 trials

  • Cardiopulmonary bypass

    Phase 4Completed1 trial

  • Sleep

    Phase 4Terminated1 trial

  • Squamous cell carcinoma of head and neck

    Phase 3Recruiting2 trials

  • Alcohol drinking

    Phase 3Completed1 trial

  • Pathologic processes

    Phase 3Completed1 trial

All 13

Stopped

  • NCT00236223TerminatedPostoperative pain

    Structural changes that stopped the type of operations used in the study

  • NCT05024825TerminatedPostoperative pain

    recruitment target not met.

  • NCT02771925TerminatedAlcoholism

    Due to poor compliance of patients in the study.

  • NCT00584779TerminatedRenal insufficiency

    See detailed description for termination reason

  • NCT00785772TerminatedRenal insufficiency

    See termination reason in detailed description.

  • NCT02599701TerminatedSleep

    Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects.

All 15

Who is developing gabapentin?

2 companies: Endo USA Inc., a Keenova Therapeutics Company and Dompé Farmaceutici S.p.A.

Companies
  • Endo USA Inc., a Keenova Therapeutics CompanyPhase 4postherpetic neuralgia, diabetic neuropathy
  • Dompé Farmaceutici S.p.APhase 1no condition

Trial sponsors

Funding

2 grants since 2023

National Institute on Aging$429K

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 1Mar 2026: 4Apr 2026: 4May 2026: 1Jun 2026: 1Jul 2026: 2Aug 2026: 1Sep 2026: 1Oct 2026: 5Nov 2026: 324 papers in 12 months

See all 56 papers on gabapentin